title: Interferon alpha-2a reduces early erythema after full-thickness skin graft in the pig.
abstract: BACKGROUND
  Skin grafting is a commonly performed procedure, but studies of changes in the levels of cytokines after skin grafting have not been reported.
  
  
  OBJECTIVE
  We examined changes in cytokines and the degree of erythema after skin grafting in pigs in the control group. Interferon alpha (IFN-alpha) was injected to reduce erythema, and subsequent changes in cytokines and the degree of erythema were examined in the experimental group.
  
  
  METHODS
  Vascular endothelial growth factor (VEGF), thrombospondin-1 (TSP1), and CD31 were examined using Western blot analysis and immunohistochemistry. The degree of erythema was measured at 2, 4, and 8 weeks using a chromometer.
  
  
  RESULTS
  In the control group, VEGF increased at 2 weeks and decreased at 4 and 8 weeks. TSP1 increased over time. CD31 increased to 4 weeks and decreased at 8 weeks. In the experimental group, VEGF was lower at 2 weeks and higher at 8 weeks than in the control group, TSP1 was higher at 2 weeks and lower at 8 weeks, and CD31 was lower at 4 and 8 weeks. Erythema in the experimental group was lower than that in the control group at 2 and 8 weeks.
  
  
  CONCLUSIONS
  IFN-alpha may be one of the agents that reduces erythema by suppressing excessive revascularization.
authors.affiliation: Department of Plastic and Reconstructive Surgery, Institute of Health Sciences, College of Medicine and Hospital Gyeongsang National University, Jinju, Republic of Korea.
authors.forename: Jun Sik
authors.initials: JS
authors.lastname: Kim
authors.forename: Daegu
authors.initials: D
authors.lastname: Son
authors.forename: Tae Hyun
authors.initials: TH
authors.lastname: Choi
authors.forename: Kihwan
authors.initials: K
authors.lastname: Han
authors.forename: Jun Hyung
authors.initials: JH
authors.lastname: Kim
authors.forename: Hyun Mi
authors.initials: HM
authors.lastname: Cho
authors.forename: Won Hee
authors.initials: WH
authors.lastname: Kim
authors.forename: Sang-Hyon
authors.initials: SH
authors.lastname: Kim
authors.forename: Nam Gyun
authors.initials: NG
authors.lastname: Kim
authors.forename: Kyung Suk
authors.initials: KS
authors.lastname: Lee
authors.forename: O Hyun
authors.initials: OH
authors.lastname: Hwang
authors.forename: Gu Seob
authors.initials: GS
authors.lastname: Roh
authors.forename: Jungbin
authors.initials: J
authors.lastname: Park
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000818:Animals; D016207:Cytokines / Q000032:analysis; D004890:Erythema / Q000209:etiology / Q000517:prevention & control*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D023421:Models, Animal; D018919:Neovascularization, Physiologic; D011994:Recombinant Proteins; D012867:Skin / Q000737:chemistry; D016038:Skin Transplantation / Q000009:adverse effects*; D013552:Swine
chemical_list: D020533:Angiogenesis Inhibitors; D016207:Cytokines; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins